Editor's Review: Week of April 1

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — Basilea Pharmaceutica receives FDA approval for its IV antibiotic

The bad — Verve Therapeutics halts gene editing trial, again
The ugly — Amylyx removes ALS treatment from market